Latest 4 stories · newest Oct 28, 2026
Enanta Pharmaceuticals announced that CEO Jay Luly will retire in February 2027. The company names Tara Kieffer as its new Chief Operating Officer and initiates a search for a successor.
Entera Bio Ltd. intends to sell securities to BVF Partners L.P. and its affiliates, through a private placement pursuant to Regulation D, Rule 506.
Enanta Pharmaceuticals entered an agreement with Jefferies LLC to sell shares of its common stock through Jefferies as an agent. This flexible funding agreement allows the company to raise capital incrementally as needed.
Enanta Pharmaceuticals announced advancement of zelicapavir into a registrational Phase 2b/3 clinical trial for high-risk RSV adults, with Phase 2b data expected in 2027, plus a pediatric Phase 2b trial starting in Q3 2026. The company estimates the oral RSV antiviral market opportunity exceeds $2 b…
The same ENTA feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/ENTA/newsSTART FREE